<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>54</volume><submitter>Byoung Soo K</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>This study investigated the outcomes of antimicrobial de-escalation (ADE) based on mortality and the incidence of multi-drug resistant (MDR) pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis and septic shock.&lt;h4>Materials and methods&lt;/h4>We retrospectively analyzed patients diagnosed with severe pneumonia requiring intensive care unit (ICU) admission and possessing negative microbiological culture results at a tertiary referral hospital in South Korea from March 2008 to July 2018.&lt;h4>Results&lt;/h4>We identified 107 patients with culture-negative pneumonia. The Acute Physiologic and Chronic Health Evaluation (APACHE) II and Sepsis-related Organ Failure Assessment (SOFA) mean scores were 20.3 ± 8.6 and 9.6 ± 3.3, respectively. Among the patients, 40 (37.4%) underwent ADE. The APACHE II, SOFA, and follow-up SOFA scores did not differ significantly between the groups, and no differences were found in ICU mortality and MDR pathogen occurrence (27.5% vs 41.8%, P = .137 and 15.0% vs 16.9% P = .794, respectively).&lt;h4>Conclusions&lt;/h4>We observed similar ICU mortality and MDR pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis/shock regardless of whether they received ADE. Additionally, ADE lowered the antimicrobial burden.</pubmed_abstract><journal>Journal of critical care</journal><pagination>14-19</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7126337</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Safety of antimicrobial de-escalation for culture-negative severe pneumonia.</pubmed_title><pmcid>PMC7126337</pmcid><pubmed_authors>Byoung Soo K</pubmed_authors><pubmed_authors>Chae-Man L</pubmed_authors><pubmed_authors>Sang Ho C</pubmed_authors><pubmed_authors>Jin-Won H</pubmed_authors><pubmed_authors>Younsuck K</pubmed_authors><pubmed_authors>Sang-Bum H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety of antimicrobial de-escalation for culture-negative severe pneumonia.</name><description>&lt;h4>Purpose&lt;/h4>This study investigated the outcomes of antimicrobial de-escalation (ADE) based on mortality and the incidence of multi-drug resistant (MDR) pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis and septic shock.&lt;h4>Materials and methods&lt;/h4>We retrospectively analyzed patients diagnosed with severe pneumonia requiring intensive care unit (ICU) admission and possessing negative microbiological culture results at a tertiary referral hospital in South Korea from March 2008 to July 2018.&lt;h4>Results&lt;/h4>We identified 107 patients with culture-negative pneumonia. The Acute Physiologic and Chronic Health Evaluation (APACHE) II and Sepsis-related Organ Failure Assessment (SOFA) mean scores were 20.3 ± 8.6 and 9.6 ± 3.3, respectively. Among the patients, 40 (37.4%) underwent ADE. The APACHE II, SOFA, and follow-up SOFA scores did not differ significantly between the groups, and no differences were found in ICU mortality and MDR pathogen occurrence (27.5% vs 41.8%, P = .137 and 15.0% vs 16.9% P = .794, respectively).&lt;h4>Conclusions&lt;/h4>We observed similar ICU mortality and MDR pathogen occurrence in patients with culture-negative pneumonia presenting with sepsis/shock regardless of whether they received ADE. Additionally, ADE lowered the antimicrobial burden.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Dec</publication><modification>2024-10-18T14:38:34.271Z</modification><creation>2020-05-22T16:36:48Z</creation></dates><accession>S-EPMC7126337</accession><cross_references><pubmed>31319347</pubmed><doi>10.1016/j.jcrc.2019.06.026</doi></cross_references></HashMap>